{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:23:36Z","timestamp":1789417416148,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K01 HL175220"],"award-info":[{"award-number":["K01 HL175220"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA-016359"],"award-info":[{"award-number":["CA-016359"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010900","name":"Yale Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017683","name":"Frederick A. DeLuca Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017683","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bvth.2026.100195","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:15:12Z","timestamp":1785190512000},"page":"100195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness analysis of emicizumab use in hospitalized older individuals with acquired hemophilia A"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5208-3387","authenticated-orcid":false,"given":"Ming Y.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4430-1860","authenticated-orcid":false,"given":"Satoko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1624-4427","authenticated-orcid":false,"given":"George","family":"Goshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4572-8794","authenticated-orcid":false,"given":"Nathorn","family":"Chaiyakunapruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9765-1197","authenticated-orcid":false,"given":"Minkyoung","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4441-7460","authenticated-orcid":false,"given":"Richard","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bvth.2026.100195_bib1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bvth.2026.100195_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/hematology.2023000462","article-title":"The role of emicizumab in acquired hemophilia A","volume":"2023","author":"Poston","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.bvth.2026.100195_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/hae.14692","article-title":"Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database","volume":"29","author":"Konstantinov","year":"2023","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.bvth.2026.100195_bib4","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bvth.2026.100195_bib5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/hae.13033","article-title":"Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data","volume":"23","author":"Amano","year":"2017","journal-title":"Haemophilia"},{"issue":"7","key":"10.1016\/j.bvth.2026.100195_bib6","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.bvth.2026.100195_bib7","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.bvth.2026.100195_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057479","article-title":"Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity","volume":"8","author":"Sampei","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bvth.2026.100195_bib9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.bvth.2026.100195_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bvth.2026.100195_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2024.100027","article-title":"Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan","volume":"1","author":"Kishi","year":"2024","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"3","key":"10.1016\/j.bvth.2026.100195_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1055\/a-2622-3483","article-title":"Early emicizumab treatment in acquired hemophilia A: impact on bypassing agent use and length of hospitalization in an Australian single-center cohort","volume":"52","author":"Pastore","year":"2026","journal-title":"Semin Thromb Hemost"},{"issue":"22","key":"10.1016\/j.bvth.2026.100195_bib14","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1182\/bloodadvances.2024013882","article-title":"Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort","volume":"8","author":"Poston","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.bvth.2026.100195_bib15","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1016\/j.bvth.2026.100195_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1055\/a-2384-3585","article-title":"Final analysis results from the AGEHA study: emicizumab prophylaxis for acquired hemophilia A with or without immunosuppressive therapy","volume":"125","author":"Shima","year":"2025","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.bvth.2026.100195_bib17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hae.14450","article-title":"Off-label use of emicizumab in persons with acquired haemophilia A and von Willebrand disease: a scoping review of the literature","volume":"28","author":"Thomas","year":"2022","journal-title":"Haemophilia"},{"issue":"11","key":"10.1016\/j.bvth.2026.100195_bib18","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.bvth.2026.100195_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bvth.2026.100195_bib20","first-page":"1","article-title":"Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999-2000 through 2015-2016","volume":"122","author":"Fryar","year":"2018","journal-title":"Natl Health Stat Rep"},{"issue":"3","key":"10.1016\/j.bvth.2026.100195_bib22","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bvth.2026.100195_bib23","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jval.2012.05.005","article-title":"Effect of acute bleeding on daily quality of life assessments in patients with congenital hemophilia with inhibitors and their families: observations from the dosing observational study in hemophilia","volume":"15","author":"Neufeld","year":"2012","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.bvth.2026.100195_bib24","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/1475-6773.13918","article-title":"Incorporating harms into the weighting of the revised Agency for Healthcare Research and Quality Patient Safety for Selected Indicators Composite (Patient Safety Indicator 90)","volume":"57","author":"Zrelak","year":"2022","journal-title":"Health Serv Res"},{"key":"10.1016\/j.bvth.2026.100195_bib25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2147\/JBM.S219573","article-title":"Thrombotic events with recombinant activated factor VII (rFVIIa) in approved indications are rare and associated with older age, cardiovascular disease, and concomitant use of activated prothrombin complex concentrates (aPCC)","volume":"10","author":"Rajpurkar","year":"2019","journal-title":"J Blood Med"},{"issue":"1","key":"10.1016\/j.bvth.2026.100195_bib26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12962-024-00552-1","article-title":"An overview of the perspectives used in health economic evaluations","volume":"22","author":"Sittimart","year":"2024","journal-title":"Cost Eff Resour Alloc"},{"issue":"1","key":"10.1016\/j.bvth.2026.100195_bib27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/M20-1392","article-title":"A health opportunity cost threshold for cost-effectiveness analysis in the United States","volume":"174","author":"Vanness","year":"2021","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.bvth.2026.100195_bib28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jacc.2025.05.009","article-title":"2025 AHA\/ACC statement on cost\/value methodology in clinical practice guidelines (update from 2014 statement): a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Kazi","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.bvth.2026.100195_bib29","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.jtha.2024.06.010","article-title":"Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A","volume":"22","author":"Hart","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"22","key":"10.1016\/j.bvth.2026.100195_bib30","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1182\/bloodadvances.2025017144","article-title":"Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A","volume":"9","author":"Schimansky","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.bvth.2026.100195_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/vox.12726","article-title":"aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model","volume":"114","author":"Kim","year":"2019","journal-title":"Vox Sang"},{"issue":"3","key":"10.1016\/j.bvth.2026.100195_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/vox.12877","article-title":"An economic analysis of different treatments for bleeding in patients with acquired haemophilia","volume":"115","author":"Kim","year":"2020","journal-title":"Vox Sang"},{"issue":"2","key":"10.1016\/j.bvth.2026.100195_bib34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14737167.2023.2160705","article-title":"Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A","volume":"23","author":"Bullano","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:07:26Z","timestamp":1788350846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327226000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2950327226000604"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100195","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of emicizumab use in hospitalized older individuals with acquired hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100195"}}